Pharmacist-Led Hospital Discharge Care—Identifying Those Who Benefit Most

Hospital discharge is among the most vulnerable transition points in care delivery for older adults with complex medication regimens.Several intervention trials have addressed this important continuity challenge, but few have demonstrated a significant effect of clinical pharmacist intervention on adverse outcomes. [1][2]2][3][4] Pevnick and colleagues 5 present the results of the Pharmacist Discharge Care (PHARM-DC) trial, a large, pragmatic randomized clinical trial evaluating whether pharmacist-led discharge medication management is associated with reduced 30-day unplanned hospital and emergency department utilization among older adults with polypharmacy or high-risk medication use.The pharmacist-led discharge transition of care intervention included medication review, discharge medication reconciliation, and efforts to improve medication adherence and safety, in addition to usual care.Usual care included medication reconciliation upon admission.Among more than 6000 older adults enrolled across 2 academic health systems, the intervention did not significantly reduce all-hospital unplanned utilization at 30 days compared with usual care.However, a prespecified subgroup of patients with low medication adherence and literacy experienced a statistically significant and clinically meaningful absolute reduction in postdischarge utilization (10.4 percentage point absolute reduction). 5The central implication is not that pharmacist-led discharge care is ineffective or lacks value, but rather that its benefits may be most pronounced in specific patient subgroups.The rationale for pharmacist involvement at hospital discharge is strong.Hospitalization commonly requires initiating medications and discontinuing, suspending, substituting, or adjusting preexisting medications during acute illness. 6For patients with multimorbidity, this often increases medication regimen complexity, the probability of discrepancies at transition points, and adverse events.Postdischarge adverse drug events are common, frequently preventable, and can lead to outpatient visits, emergency department utilization, and rehospitalization. 7Prior randomized clinical trials and systematic reviews demonstrated that pharmacist-led medication reconciliation, review, and patient education reduced medication discrepancies and preventable adverse drug events. 1Nevertheless, evidence linking these interventions to downstream reductions in mortality and health care utilization has been inconsistent, potentially limiting the business case for sustained operational investment. 4e PHARM-DC trial 5 advances this literature in 2 ways that are particularly relevant for health system leadership.First, to our knowledge, it is the most pragmatic and operationally grounded trial to date.The intervention was implemented within routine workflows, under staffing constraints and evolving usual care, with variable fidelity and measurable contamination-conditions that reflect what hospitals face when they attempt to scale pharmacy services. 5Second, the trial inclusion criteria selected for a population we commonly consider at high medication-related risk (polypharmacy or high-risk medication exposure), yet still demonstrated a neutral effect on overall 30-day health care utilization.This should prompt a reframing: broad deployment of this intervention may be effective for medication safety, but not necessarily efficient for utilization reduction unless it is targeted to those with the greatest modifiable risk.The heterogeneity of treatment effect needs to be considered, as the data suggest that the returns on pharmacist time are not evenly distributed.Without a change in staffing models, pharmacists cannot see all patients efficiently, and maybe do not need to.In practical terms, the question shifts from "Should hospitals invest in pharmacist discharge care?" to "How should hospitals deploy pharmacist expertise to maximize benefit per unit of effort?"